Q2 2021 Results - Reimagining Medicine slide image

Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations Cardiovascular, Renal and Metabolic 57 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation